Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo.

Autor:	Landgraf M; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia., Lahr CA; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia., Sanchez-Herrero A; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia., Meinert C; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia., Shokoohmand A; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia., Pollock PM; 2School of Biomedical Science, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, Australia., Hutmacher DW; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.; 3Australian Research Council (ARC) Training Centre in Additive Biomanufacturing, Queensland University of Technology, Brisbane, Australia., Shafiee A; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.; 4UQ Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD Australia., McGovern JA; 1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.
Jazyk:	angličtina
Zdroj:	Bone research [Bone Res] 2019 Oct 21; Vol. 7, pp. 31. Date of Electronic Publication: 2019 Oct 21 (Print Publication: 2019).
DOI:	10.1038/s41413-019-0072-9
Abstrakt:	Advanced prostate cancer (PCa) is known for its high prevalence to metastasize to bone, at which point it is considered incurable. Despite significant effort, there is no animal model capable of recapitulating the complexity of PCa bone metastasis. The humanized mouse model for PCa bone metastasis used in this study aims to provide a platform for the assessment of new drugs by recapitulating the human-human cell interactions relevant for disease development and progression. The humanized tissue-engineered bone construct (hTEBC) was created within NOD-scid IL2rg null (NSG) mice and was used for the study of experimental PC3-Luc bone metastases. It was confirmed that PC3-Luc cells preferentially grew in the hTEBC compared with murine bone. The translational potential of the humanized mouse model for PCa bone metastasis was evaluated with two clinically approved osteoprotective therapies, the non-species-specific bisphosphonate zoledronic acid (ZA) or the human-specific antibody Denosumab, both targeting Receptor Activator of Nuclear Factor Kappa-Β Ligand. ZA, but not Denosumab, significantly decreased metastases in hTEBCs, but not murine femora. These results highlight the importance of humanized models for the preclinical research on PCa bone metastasis and indicate the potential of the bioengineered mouse model to closely mimic the metastatic cascade of PCa cells to human bone. Eventually, it will enable the development of new effective antimetastatic treatments. Competing Interests: Competing interestsThe authors declare the following competing interest(s): C.M. is a founder, shareholder, and director of GELOMICS PTY LTD, a start-up company developing and distributing hydrogels for 3D cell culture applications. D.W.H. is a founder and shareholder of GELOMICS PTY LTD. All other authors declare no competing interests. (© The Author(s) 2019.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu